49.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$49.27
Aprire:
$49.22
Volume 24 ore:
175.36K
Relative Volume:
0.21
Capitalizzazione di mercato:
$2.77B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
46.18
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
-0.24%
1M Prestazione:
+12.28%
6M Prestazione:
+60.83%
1 anno Prestazione:
+45.35%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
49.45 | 2.76B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
143.79 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.92 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.205 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.77 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
430.10 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-01-03 | Ripresa | Jefferies | Buy |
2021-12-01 | Ripresa | Jefferies | Buy |
2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-06-15 | Ripresa | Jefferies | Hold |
2019-11-08 | Downgrade | Berenberg | Buy → Hold |
2019-11-07 | Downgrade | Stifel | Buy → Hold |
2019-11-06 | Downgrade | Jefferies | Buy → Hold |
2018-11-12 | Reiterato | B. Riley FBR | Buy |
2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
2017-10-19 | Iniziato | FBR & Co. | Buy |
2017-09-19 | Downgrade | Stifel | Buy → Hold |
2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
2017-07-14 | Iniziato | Janney | Neutral |
2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
2015-11-05 | Reiterato | Northland Capital | Outperform |
2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Is it time to cut losses on Supernus Pharmaceuticals Inc.Breakout Watch & Capital Efficient Trade Techniques - newser.com
Why Supernus Pharmaceuticals Inc. stock remains undervaluedTrend Reversal & Precise Buy Zone Identification - newser.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastGlobal Trade Effects & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know - Yahoo Finance
Published on: 2025-10-13 06:52:20 - newser.com
What MACD signals say about Supernus Pharmaceuticals Inc.Wall Street Watch & Daily Stock Trend Watchlist - newser.com
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines - Yahoo Finance
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com
Did Piper Sandler’s Upgrade on Onapgo Just Shift Supernus Pharmaceuticals' (SUPN) Investment Narrative? - Sahm
Supernus CEO Khattar sells $3m in shares By Investing.com - Investing.com Canada
Insider Sell Alert: NEWHALL CHARLES W III Sells 25,000 Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus
Supernus Pharmaceuticals Executives Sell Shares - TradingView
SUPN Crosses Above Average Analyst Target - Nasdaq
Supernus Pharmaceuticals Shares Rise After Piper Sandler Upgrade - MarketScreener
Supernus Pharmaceuticals: A Rising Pharma Contender? - StocksToTrade
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know - TradingView
SUPN: Piper Sandler Raises Price Target to $65 and Upgrades Rati - GuruFocus
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Piper Sandler Upgrades Supernus Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $65 From $40 - MarketScreener
Can Supernus Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com
How Supernus Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:01:01 - newser.com
Supernus (SUPN) Receives Upgraded Rating Amid Promising Product Outlook - GuruFocus
How to use Fibonacci retracement on Supernus Pharmaceuticals Inc.2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Supernus Pharmaceuticals (SUPN): Exploring Valuation After Three-Month Share Price Surge - Sahm
Is now a turning point for Supernus Pharmaceuticals Inc.July 2025 Earnings & Real-Time Sentiment Analysis - newser.com
Supernus Pharmaceuticals Hits New 52-Week High of $49.66 - Markets Mojo
Will Supernus Pharmaceuticals Inc. rebound enough to break evenDollar Strength & Weekly Top Performers Watchlists - newser.com
How geopolitical tensions affect Supernus Pharmaceuticals Inc. stockCPI Data & Comprehensive Market Scan Insights - newser.com
Why Supernus Pharmaceuticals Inc. stock could be next big winnerJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Using R and stats models for Supernus Pharmaceuticals Inc. forecasting2025 Macro Impact & Reliable Volume Spike Trade Alerts - newser.com
Is Supernus Pharmaceuticals Inc. stock poised for growthPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Is Supernus Pharmaceuticals Inc. stock cheap compared to fundamentalsAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Wall Street Zen Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Hold - Defense World
Smart tools for monitoring Supernus Pharmaceuticals Inc.’s price actionQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
Real time social sentiment graph for Supernus Pharmaceuticals Inc.Trade Volume Summary & Real-Time Buy Zone Alerts - newser.com
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by GAMMA Investing LLC - Defense World
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Khattar Jack A. | President, CEO |
Oct 09 '25 |
Sale |
50.57 |
59,900 |
3,029,336 |
1,206,578 |
NEWHALL CHARLES W III | Director |
Oct 09 '25 |
Sale |
50.77 |
25,000 |
1,269,234 |
104,644 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):